ArticleDermatology and therapy2026
A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionReal-world management of moderate-to-severe atopic dermatitis (AD) may involve treatment interruptions. This indirect comparison evaluated the efficacy of lebrikizumab, dupilumab, and tralokinumab monotherapy in achieving week-52 response at variable adherence levels.
methodsThis indirect comparative analysis used data from the induction (week 0-16) and maintenance (week 16-52) phases of the ADvocate, SOLO, and ECZTRA monotherapy trials. A novel Durability Index (DI) was used to estimate week 52 response from week 0 at variable maintenance adherence levels. To estimate the impact of adherence, reported maintenance responses in the continuous treatment (100% adherence) and withdrawal (0% adherence) arms were weighted by the assumed proportion of patients remaining on treatment, with intermediate adherence levels estimated by linear interpolation. Responses included an Investigator's Global Assessment (IGA) score of 0/1 or ≥ 75% improvement in Eczema Area Severity Index (EASI 75). Odds ratios (ORs) and risk differences (RD) with 95% confidence intervals (CIs) were estimated.
resultsLebrikizumab had significantly greater efficacy than dupilumab of achieving week 52 IGA 0/1 for adherence rates between 0% (OR 3.4, 95% CI 1.3-11.3) and 78% (OR 1.5, 1.0-2.5) and EASI 75 for adherence rates between 0% (OR 2.6, 1.4-5.0) and 63% (OR 1.4, 1.0-2.0). At higher adherence rates, lebrikizumab had comparable efficacy to dupilumab. Lebrikizumab had significantly better efficacy than tralokinumab of achieving week 52 responses for all adherence rates for IGA 0/1 (0%: OR 2.5, 1.1-5.9; 100%: OR 2.6, 1.6-4.2) and EASI 75 (0%: OR 5.3, 2.8-10.4; 100%: OR 3.2, 2.2-4.8). Dupilumab had significantly better efficacy than tralokinumab of achieving IGA 0/1 at adherences rates above 69% and EASI 75 across all adherence rates. RDs were consistent with differences observed for ORs.
conclusionsIn this indirect comparative analysis, lebrikizumab was associated with comparable or superior efficacy relative to dupilumab and superior efficacy relative to tralokinumab across all adherence rates in moderate-to-severe AD. As the DI is a novel metric, these findings should be interpreted cautiously, and independent validation of the DI is needed to ensure its clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.